Semaglutide 2.4 mg (Wegovy) : A once-weekly injectable GLP-1 receptor agonist approved by the MHRA for chronic weight management
This product is supplied exclusively for laboratory and scientific research
For example, taking 680 mg (one capsule of the Pure Encapsulations formula) twice daily between meals is an effective way to maintain steady blood plasma levels without overwhelming the intestinal transporters
From a customer perspective, they should not be interpreted as instructions, safety advice or personal-use guidance
Ozempic may contribute to an increased risk for thyroid c-cell tumors, acute pancreatitis, gallbladder disease, hypoglyceia, acute kidney injury, severe GI side effects, and an increased risk for worsening of diabetic retinopathy in people with type 2 diabetes
Handling This compound blend should be handled using appropriate laboratory safety procedures by trained professionals in a controlled research environment